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Background: The aim of this study in patients with acute posterior ischemic stroke (PS) and atrial 
fibrillation (AF) were to evaluate (1) the risks of recurrent ischemic event and severe bleeding and 
(2) these risks in relation with oral anticoagulant therapy (OAT) and its timing.  
Methods: Patients with PS were prospectively included; the outcome events of these patients were 
compared with those of patients with anterior stroke (AS) which were taken from previous 
registries. The primary outcome was the composite of: stroke recurrence, TIA, symptomatic 
systemic embolism, symptomatic cerebral bleeding and major extracranial bleeding occurring 
within 90 days from acute stroke. 
Results: A total of 2,470 patients were available for the analysis: 473 (19.1%) with PS and 1,997 
(80.9%) AS. Over 90 days, 213 (8.6%) primary outcome events were recorded: 175 (8.7%) in 
patients with AS and 38 (8.0%) in those with PS. In patients who initiated OAT within 2 days, the 
primary outcome occurred in 5 out of 95 patients (5.3%) with PS compared to 21 out of 373 
patients (4.3%) with AS (OR 1.07; 95% CI 0.39-2.94). In patients who initiated OAT between days 
3 and 7, the primary outcome occurred in 3 out of 103 patients (2.9%) with PS compared to 26 out 
of 490 patients (5.3%) with AS (OR 0.54; 95% CI 0.16-1.80). 
Conclusions: Patients with posterior or anterior stroke and AF appear to have similar risks of 
ischemic or hemorrhagic events at 90 days with no difference concerning the timing of initiation of 
OAT. 
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Introduction 
Anticoagulant therapy has been proven to be highly effective for secondary stroke prevention in 
patients with atrial fibrillation (AF) (1). Deciding when to initiate this therapy in patients with acute 
ischemic stroke and AF is a challenge because the risks of both early recurrent ischemic stroke and 
hemorrhagic transformation are highest in the days immediately following the acute event (2). 
Indeed, there are no definitive data on this issue and current guidelines do not adequately address 
when to best start oral anticoagulation with even greater uncertainties in patients with acute 
posterior circulation stroke (3). In fact, it has been described that posterior circulation stroke was 
associated with a higher early risk for subsequent stroke compared to carotid events; while there 
was a lower risk of hemorrhagic transformation (4-6).  
This international prospective multicenter study included patients with acute ischemic posterior 
circulation stroke and AF, with the principle aims of evaluating at 90 days from an acute event for 
(1) the risks of recurrent ischemic embolic event and severe bleeding (both intra and extracranial) as 
well as (2) the risks of recurrent ischemic embolic event and bleeding in relation to the timing of the 
start of anticoagulant therapy. Moreover, the rates of ischemic events for patients with anterior or 
posterior circulation stroke were compared. The data for patients with anterior circulation stroke 
came from previously published studies. The protocol and the statistical analyses were discussed 
and approved by all the co-authors before initiating the collect of the data. 
  
Methods 
This observational study was performed between October 2018 and June 2019 and included 
consecutive patients with acute ischemic posterior circulation stroke and previous or newly 
diagnosed AF without contraindications to anticoagulation. Overall, 19 Stroke Units across Europe, 
North America and Asia participated. The study was approved by the local institutional review 
boards, whenever required. 
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Posterior circulation stroke was defined as any acute stroke occurring in the territories of the 
posterior cerebral arteries (deep and or superficial), brainstem or cerebellum (7) visible on 
neuroimaging. 
On admission, stroke severity was assessed using the National Institutes of Health Stroke Scale 
(NIHSS) and a cerebral computed tomography examination without contrast or cerebral magnetic 
resonance imaging (MRI) was performed on all patients to exclude for intracranial hemorrhage. 
Thrombolysis treatment and/or mechanical thrombectomy were performed as per standard local 
protocol, in accordance with international guidelines. All participating Stroke Units provided 
standard Stroke Unit care and monitoring. Physicians were free to decide on any administration of 
anticoagulant treatment (warfarin, apixaban, edoxaban, dabigatran or rivaroxaban), as well as their 
timing. 
A second brain computed tomography scan or MRI was to be performed 24 to 72 h from stroke 
onset. Hemorrhagic transformation (HT) was defined as any degree of hyperdensity within the area 
of low attenuation and was classified as either hemorrhagic infarction or parenchymal hematoma 
(8,9). HT was considered symptomatic whenever it was associated with a decline in neurological 
status (an increase of 4 points in NIHSS) in the absence of any bleeding evidence on the first 
computed tomography (10). The sites and sizes of the qualifying infarcts were determined 
according to standard templates (7): (1) small, when a lesion was ≤1.5 cm and large, when a lesion 
was >1.5 cm. 
Risk factors and the outcome events of patients with posterior circulation stroke were compared 
with those of patients with anterior circulation stroke. The latter data came from the RAF and RAF 
NOACs (Non-vitamin K oral anticoagulants) studies (11,12) that were prospective observational 
studies carried out between January 2012 and March 2014 at 29 Stroke Units and between April 
2014 and June 2016 at 35 stroke units respectively, across Europe, United States and Asia. Both the 
RAF studies enrolled consecutive patients with acute ischemic stroke and known or newly 
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diagnosed AF without contraindications to anticoagulation. The same inclusion criteria used for 
RAF and RAF NOACs was used for the present study. 
 
Risk Factors 
Data on risk factors were collected: age, sex, history of hypertension (blood pressure ≥140/90 mm 
Hg at least twice before stroke or already under treatment with antihypertensive drugs), history of 
diabetes mellitus [fasting glucose level ≥126 mg/dL (7 mmol/L) preprandial on 2 examinations, 
glucose level ≥200 mg/dL (11.1 mmol/L) postprandial, or HbA1c ≥6.5%, or under antidiabetic 
treatment], current cigarette smoking, hyperlipidemia [total cholesterol ≥200 mg/dL (11.1 mmol/L) 
or triglycerides ≥140 mg/dL (7.8 mmol/L) or already under lipid lowering therapy], history of 
symptomatic ischemic heart disease (myocardial infarction, history of angina pectoris, or existence 
of multiple lesions on thallium heart isotope scan or evidence of coronary disease on coronary 
angiography), history of symptomatic peripheral arterial disease (intermittent claudication of 
presumed atherosclerotic origin; or ankle/arm systolic blood pressure ratio <0.85 in either leg at 
rest; or history of intermittent claudication with previous leg amputation, reconstructive surgery, or 
angioplasty), alcohol abuse (≥300 g per week), obesity (body mass index ≥30 kg/m2), or previous 
stroke/transient ischemic attack (TIA). White matter changes (leukoaraiosis defined on the first 
computed tomography examination as ill-defined and moderately hypodense areas of ≥5 mm 
according to published criteria) were investigated (13). Leukoaraiosis in the deep white matter was 
dichotomized into absent versus mild, moderate, or severe. Other baseline variables obtained at 
admission for all patients included fasting serum glucose, fasting serum cholesterol (total, high-
density lipoprotein, and low-density lipoprotein), platelet count, International Normalized Ratio, 
activated partial thromboplastin time, systolic blood pressure, and diastolic blood pressure. Data on 
the use of any antiplatelet, anticoagulants, or revascularization therapy (thrombolytic agents and/or 
mechanical thrombectomy), before admission, at baseline, and during the follow-up period, were 
recorded. The CHA2DS2-VASc score (2 points for a history of stroke or age ≥75 years and 1 point 
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each for age 65 to 74 years, a history of hypertension, diabetes, cardiac failure, and vascular 
disease) before the index event was also calculated (14). 
AF was categorized as: paroxysmal (episodes terminating spontaneously within seven days), 
persistent (episodes lasting more than seven days or requiring pharmacological and/or electrical 
cardioversion and permanent (persisting for more than one year, either because cardioversion failed 
or was not pursued (15). For the purpose of the present study, AF was categorized into two types: 
paroxysmal AF or sustained (persistent or permanent) AF. 
 
Evaluation of Outcome 
Patients were followed-up prospectively by face-to-face, telephone interviews or a review of 
available medical charts whenever a patient had died during follow-up. Whenever an outcome event 
occurred, patients were requested to consign any related documentation during a face-to-face visit. 
Study outcomes were (1) recurrent ischemic cerebrovascular events (stroke or TIA) and 
symptomatic systemic embolisms; (2) symptomatic cerebral bleedings (intracerebral hemorrhage) 
and major extracerebral bleeding at 90 days. The primary study outcome was the composite of 
stroke, TIA, symptomatic systemic embolism, symptomatic cerebral bleeding, and major 
extracerebral bleeding. Disability and mortality at 90 days were also assessed using the modified 
Rankin Scale score (mRS). Functional outcome was defined as either non-disabling (mRS 0–2) or 
disabling (mRS 3–5).  
Stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin in a 
site consistent with the territory of a major cerebral artery and categorized as ischemic or 
hemorrhagic. HTs found on neuroimaging 24 to 72 hours after onset were not considered outcome 
events, unless they were symptomatic. TIA was defined as a transient episode of neurological 
dysfunction caused by focal brain ischemia without acute infarction. Systemic embolism was 
defined as an acute vascular occlusion of an extremity or organ, confirmed by imaging, surgery, or 
autopsy. Major extra-cerebral bleeding was defined as a reduction in the hemoglobin level of at 
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least 2 g per deciliter, requiring blood transfusion of at least 2 U, or symptomatic bleeding in a 
critical area or organ (16). 
 
Statistical Analysis 
Patient characteristics are presented as mean and standard deviations for continuous variables and 
as absolute numbers and percentages for categorical variables. Differences in the characteristics of 
patients with posterior or anterior circulation stroke were calculated using χ2 test for nominal 
variables and ANOVA for continuous variables. Furthermore, differences in the characteristics of 
patients with or without outcome event at 90 days were calculated using χ2 test for nominal 
variables whereas ANOVA was used for continuous variables. A multivariable analysis was 
performed using logistic regression to seek independent predictors of outcome events. The variables 
included in the model were: age, sex, vascular risk factors, type of anticoagulant, leukoaraiosis, 
lesion size, type of AF and pacemaker. 
Given that data relevant to anterior and posterior circulation strokes were collected over different 
time periods, a multivariable analysis that adjusted for these time period differences was also 
performed. For this analysis, the variable “time period of data collection” was classified as 0 for the 
period 2014-2016 and 1 for the period 2018-2019, and then included in the multivariable model. 
Moreover, a multivariable model adjusted for any possible effects associated with the different 
times of initiating the oral anticoagulants was utilized.  
Survival function and empirical cumulative hazards function were estimated using Kaplan–Meier 
estimators for the investigated subgroups of patients; the differences between survival functions 
were tested using the Log rank statistic (or Mantel–Haenszel test) that in the case of large samples 
has an asymptotic Chi-square distribution (17). Patients were censored at the time of an outcome 
event, death, or if they were lost to follow-up. In order to best estimate associations, we used odds 
ratios (OR) for multivariable logistic models; a two-sided p-value<0.05 was considered significant. 
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All statistical analyses were performed using the IBM SPSS Statistics version 25.0 (IBM 
Corporation, Somers, NY). 
The study fulfilled 20/22 items listed in the STROBE for observational studies (18).  
 
Results 
A total of 473 patients with posterior circulation stroke were prospectively included; the data of 
these patients were compared with the data of 1,997 patients with anterior circulation stroke taken 
from the RAF (969) and RAF NOACs (1028) studies. This population of 2,470 patients (1,306 
females, 52.9%) were available for the analysis. 
The baseline characteristics of the patients are listed in Table 1. Posterior circulation stroke patients 
were more likely to have the following: lower baseline NIHSS-score, diabetes mellitus, 
hypertension, hyperlipidemia, paroxysmal AF, congestive heart failure, implanted pacemaker, 
history of myocardial infarction and peripheral arterial disease, CHA2DS2-VASc>4 and large lesion 
size. Moreover, patients with posterior circulation stroke were also more likely to be on treatment 
with direct oral anticoagulant after the index stroke; 22 patients with posterior circulation stroke had 
stenosis ≥50% or occlusion of the basilar artery. 
 
Outcome Events 
Over 90 days of follow-up, 213 (8.6%) outcome events were recorded: 175/1997 (8.7%) in patients 
with anterior circulation stroke and 38/473 (8.0%) in patients with posterior circulation stroke. In 
Table 2 the outcome events are summarized according to anterior or posterior circulation. There 
were no significant differences between the two groups regarding all types of outcome events 
(combined, ischemic or hemorrhagic). Considering the entire population, on multivariable analysis, 
diabetes mellitus (OR 1.66; 95% CI 1.20-2.31), pacemaker (OR 1.73; 95% CI 1.06-2.82), large 
lesion size (OR 1.81; 95% CI 1.26-2.63) and treatment with warfarin versus NOACs (OR 2.76; 
95% CI 1.77-4.29) were associated with combined outcome events, while diabetes mellitus (OR 
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1.60; 95% CI 1.06-2.44), treatment with warfarin versus NOACs (OR 2.90; 95% CI 1.68-5.03) and 
NIHSS on admission (OR 1.02 for each point increase; 95% CI 1.00-1.05) were associated with 
ischemic outcome events. Furthermore, diabetes mellitus (OR 1.63; 95% CI 1.01-2.62), treatment 
with warfarin versus NOACs (OR 2.23; 95% CI 1.18-4.23) and large lesion size (OR 2.91; 95% CI 
1.61-5.20) were associated with hemorrhagic outcome events. Adjusting for different time period 
collections, no significant differences were evidenced between anterior and posterior circulation 
strokes, regarding all types of outcome events: OR 0.79 (95% CI 0.10-6.11) for combined end-
point, OR 1.23 (95% CI 0.16-9.55) for ischemic end-point and OR 2.11 (95% CI 0.27-16.53) for 
hemorrhagic end-point.  
The outcome events according to the time of oral anticoagulant therapy initiation in patients with 
anterior or posterior circulation stroke are reported in both Table 3 and Figure 1: 2 out of 95 
patients (2.1%) with posterior circulation stroke who initiated oral anticoagulant therapy within 2 
days from index stroke had an ischemic endpoint, compared to 16 out of 373 patients (4.3%) with 
anterior circulation stroke who initiated oral anticoagulant therapy within the same time period (OR 
0.48; 95% CI 0.11-2.12). While 1 of the 103 patients (0.9%) with posterior circulation stroke who 
initiated oral anticoagulant therapy between day 3 and 7 from index stroke, had an ischemic 
endpoint, compared to 19 out of 490 patients (3.8%) with anterior circulation stroke who initiated 
oral anticoagulant therapy within the same time period (OR 0.24; 95% CI 0.03-1.84). Furthermore, 
3 out of 95 patients (3.1%) with posterior circulation stroke who initiated oral anticoagulant therapy 
within 2 days from index stroke had a hemorrhagic endpoint compared to 5 out of 373 patients 
(1.3%) with anterior circulation stroke who initiated oral anticoagulant therapy within the same 
time period (OR 2.37; 95% CI 0.56-10.11). Whereas 2 of 103 patients (1.9%) with posterior 
circulation stroke who initiated oral anticoagulant therapy between days 3 and 7 from index stroke 
had a hemorrhagic endpoint, compared to 8 out of 490 patients (1.6%) with anterior circulation 
stroke who initiated oral anticoagulant therapy within the same time period (OR 1.19; 95% CI 0.25-
5.70). Regarding the combined endpoint (ischemic and hemorrhagic), 5 out of 95 patients (5.3%) 
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with posterior circulation stroke who initiated oral anticoagulant therapy within 2 days from index 
stroke had an endpoint, compared to 21 out of 373 patients (4.3%) with anterior circulation stroke 
who initiated oral anticoagulant therapy within the same time period (OR 0.93; 95% CI 0.34-2.54). 
While 3 out of 103 patients (2.9%) with posterior circulation stroke who initiated oral anticoagulant 
therapy between days 3 and 7 from index stroke had an endpoint, compared to 26 out of 490 
patients (5.3%) with anterior circulation stroke who initiated oral anticoagulant therapy within the 
same time period (OR 0.54; 95% CI 0.16-1.80). The risk of any outcome event appeared to be 
higher after starting anticoagulant therapy >7 days from index stroke for both groups. Adjusting for 
the different times of oral anticoagulant initiation from index stroke, no significant difference was 
observed between anterior and posterior circulation strokes regarding combined outcome event (OR 
8.31; 95% CI 0.68-100.88). This analysis was not performed for either ischemic or hemorrhagic 
outcome events, due to the low number of events in both arms. 
The outcome events in patients with posterior circulation stroke associated with lesion size are 
reported in Table 4 and Figure 2: 2 out of 116 patients (1.7%) with small lesion had a hemorrhagic 
outcome event within 90 days, compared to 18 out of 352 (5.0%) of patients with large lesion (Log 
rank test, p=0.05). 
At 90 days, 763 out of 1997 patients (38.2%) with anterior circulation stroke and 187 out of 473 
patients (39.5%) with posterior circulation stroke had an mRS>2 (OR 0.95; 95% CI 0.77-1.16); 123 
out of 1,997 (6.2%) with anterior circulation stroke and 41 out of 473 patients (8.7%) with posterior 
circulation stroke died (OR 0.69; 95% CI 0.48-1.00).  
 
Discussion 
This study showed that patients with posterior circulation stroke and AF had, at 90 days, an 8.0% 
risk of combined outcome events that was similar to that of anterior circulation stroke patients 
(8.7%). The observed risk of ischemic outcome events, though not statistically significant, was 
lower in patients with posterior circulation stroke, compared to those with anterior circulation 
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stroke. Moreover, it seems that patients with posterior circulation stroke had a non-statistically 
significant higher risk for hemorrhagic outcome events, compared to those patients with anterior 
circulation stroke. With regard to the timing of initiation of oral anticoagulant treatment, the 
combined outcome event risk in patients with posterior circulation stroke, who had initiated the 
therapy in the first 7 days, was 8.2%, compared to 10.9% in patients with anterior circulation stroke. 
Our findings suggest that, when deciding the time to initiate oral anticoagulation, the location of 
stroke, either anterior or posterior, does not predict the risk of outcome events. Also, the functional 
final outcome at 90 days using mRS was similar between the two groups, while the NIHSS revealed 
a less severe stroke syndrome in posterior circulation stroke patients compared to anterior 
circulation stroke patients. This finding can be attributed to the fact that NIHSS includes more 
symptoms of the anterior than the posterior circulation; patients with posterior circulation stroke 
have a score lower despite similar stroke severity (19). 
In patients with posterior circulation stroke and AF the risk of intracerebral bleeding in patients 
with small lesion was low; suggesting an earlier initiation of oral anticoagulant therapy. Several 
randomized trials are ongoing to further investigate this specific research question (2). 
Several studies have reported that patients with posterior and anterior circulation stroke did not 
differ in terms of the prevalence of vascular risk factors (20-22). Other studies have reported 
differences in etiology between the two groups (19, 23-26). In our study, patients with posterior 
circulation stroke appeared to have a higher prevalence of risk factors. Of note, all of the above 
studies included patients with anterior or posterior circulation stroke without considering etiology 
while our study included only patients with acute stroke and AF.  
Our study has several limitations. First, due to the non-randomized nature of the study, our results 
may be influenced by several confounders including a selection bias for treatment, even if adjusted 
statistical models were used in the attempt to control them. Second, a central adjudication of the 
outcome events was not performed but rather, these events were assessed by the local investigators. 
Third, in observational studies it is not possible to adjust for physician biases associated with 
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prescription of oral anticoagulant timings and agents. Another potentially important factor is the 
difference in time period between posterior strokes and anterior strokes; the former being recent and 
the latter being from previously published studies with enrolment before 2014 (the RAF and RAF-
DOAC studies). There could therefore be important secular trends accounting for different event 
rates (e.g changes in NOAC use), improved general stroke care (e.g. possibly less bridging), or 
different oral anticoagulant therapy timing. In fact, regarding changes in oral anticoagulant type 
use, in the posterior stroke population, which was   more recently collected, 66% of the patients 
were treated with NOACs compared to 55% of the patients in the anterior stroke population. 
Conversely, 27% of the patients with anterior stroke were treated with warfarin, compared to 19% 
of the patients in the posterior stroke population. 
Furthermore, in the posterior circulation stroke group, compared to the anterior circulation stroke 
group, a lower number of patients were treated with bridging therapy with full dose of enoxaparin 
(18% versus 45%). It is plausible that this disparity was influenced by the fact that, in the RAF 
studies, patients treated with bridging therapy had a worse outcome, compared to those treated 
without bridging therapy (27). These differences might have influenced the results, even if 
multivariable models were used in the attempt to adjust them. 
There are several ongoing randomized controlled trials to overcome the limitations of these 
observational data (28) and furthermore, subgroup analyses of these trials are needed to determine 
how the timing of anticoagulation might interact with ischemic stroke location. 
The strengths of our study include its prospective design, the multi-center nature and relatively 
large sample size. 
In conclusion, we observed that patients with posterior or anterior stroke and AF, had similar risks 
of ischemic and hemorrhagic events at 90 days. The timing of oral anticoagulant initiation did not 
appear to influence the association between stroke location and outcome events. 
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Table 1: Baseline characteristics stratified by stroke location 
 Anterior Stroke 
(n=1997) 
Posterior stroke 
(n=473) 
 
P 
 
Age (years) mean 
                    Median 
 
76.39,7 
77.00 
 
77.69.6 
79.00 
 
0.6 
NIHSS on admission mean 
                                   Median 
8.56.7 
6.00 
6.86.9 
4.00 
0.02 
Male sex 924 (46.3%) 240 (50.7%) 0.08 
Diabetes mellitus 443 (22.2%) 126 (26.6%) 0.04 
History of hypertension 1557 (78.0%) 391 (82.7%) 0.02 
Hyperlipidemia 675 (33.8%) 190 (40.2%) 0.009 
Paroxysmal atrial fibrillation 842 (42.2%) 238 (50.3%) 0.001 
History of stroke/TIA 520 (26.0%) 129 (27.3%) 0.5 
Current smoker 188 (9.4%) 46 (9.7%) 0.8 
Alcohol 127 (6.4%) 55 (11.6%) 0.0008 
Congestive heart failure 172 (8.6%) 60 (12.7%) 0.006 
History of myocardial infarction 264 (13.2%) 103 (21.8%) 0.0001 
History of peripheral artery disease 172 (8.6%) 55 (11.6%) 0.04 
Therapy with warfarin after index event 
- Bridging with full dose enoxaparin 
536 (26.8%) 
243 (45.3%) 
89 (18.8%)* 
16 (18.0%) 
0.004 
Therapy with direct anticoagulants after 
index event 
- Apixaban 
- Dabigatran 
- Edoxaban 
- Rivaroxaban 
- Bridging with full dose enoxaparin 
1098 (55.0%) 
 
338 (30.8%) 
405 (36.9%) 
0 
355 (32.3%) 
112 (10.2%) 
314 (66.3%)* 
 
129 (41.1%) 
90 (28.7%) 
18 (5.7%) 
77 (24.5%) 
18 (5.7%) 
0.0001 
No oral anticoagulants after index event 363 (18.2%) 35 (7.4%)* 0.0001 
Mean time of anticoagulant therapy 
initiation (days) 
11.415.3 12.319.9 0.2 
Pacemaker 141 (7.1%) 32 (6.8%) 0.8 
Lesion size >1.5 cm 1169 (58.5%) 357 (75.5%) 0.001 
Leukoaraiosis 988 (49.5%) 318 (67.2%) 0.0001 
rtPA and/or thrombectomy 535 (26.8%) 8 (16.9%) 0.0001 
Hemorrhagic transformation (24-72 hours) 214 (10.7%) 75 (15.9%) 0.001 
CHA2DS2-VASc > 4 1539 (77.1%) 415 (87.7%) 0.001 
 
*35 patients missing 
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Table 2: Association of stroke location (anterior vs. posterior) with outcome events 
 Posterior 
circulation stroke 
(n=473) 
 
Anterior 
circulation stroke 
(n=1997) 
Odds ratios (95% Confidence Interval) 
Combined endpoint 38 (8.0%) 175 (8.7%) Unadjusted 0.94 (0.65 – 1.36) 
Adjusted     0.79 (0.53 – 1.19) 
Ischemic endpoint 18 (3.8%) 102 (5.1%) Unadjusted 0.73 (0.44 – 1.23) 
Adjusted     0.67 (0.38 – 1.16) 
Hemorrhagic endpoint 20 (4.2%) 73 (3.7%) Unadjusted 1.16 (0.70 – 1.93) 
Adjusted.    0.93 (0.54 – 1.62) 
 
 
 
 
Table 3: Association of outcome events with the timing of oral anticoagulant therapy initiation after 
index event stratified by stroke location 
 
Anterior stroke* 
 Combined endpoint Ischemic endpoint Hemorrhagic endpoint 
0-2 days (n=373) 21 (5.6%) 16 (4.3%) 5 (1.3%) 
3-7 days (n=490) 26 (5.3%) 19 (3.8%) 8 (1.6%) 
8-14 days (n=373) 30 (8.0%) 14 (3.8%) 17 (4.5%) 
>14 days (n=379) 31 (8.2%) 19 (5.0%) 14 (3.7%) 
No therapy with oral 
anticoagulants (n=363) 
61 (16.8%) 34 (9.4%) 29 (8.0%) 
*19 patients missing 
 
Posterior stroke* 
 Combined endpoint Ischemic endpoint Hemorrhagic endpoint 
0-2 days (n=95) 5 (5.3%) 2 (2.1%) 3 (3.1%) 
3-7 days (n=103) 3 (2.9%) 1 (0.9%) 2 (1.9%) 
8-14 days (n=88) 6 (6.8%) 3 (3.4%) 4 (4.5%) 
>14 days (n=152) 18 (11.8%) 11 (7.2%) 7 (4.6%) 
No therapy with oral 
anticoagulants (n=35) 
6 (17.1%) 2 (5.7%) 4 (11.4%) 
 
 
 
Table 4: Association of outcome events with lesion size stratified by stroke location 
 
 Small lesion 
(n=116) 
Large lesion 
(n=352) 
 
Log Rank (Mantel-Cox) 
Combined endpoint 7 (6.0%) 30 (8.4%) 0.09 
Ischemic endpoint 5 (4.3%) 12 (3.4%) 0.9 
Hemorrhagic endpoint 2 (1.7%) 18 (5.0%) 0.05 
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Figure 1: Kaplan-Meier curves of outcome events stratified by timing of initiation of oral anticoagulants in patients with anterior or posterior stroke 
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Figure 2: Kaplan-Meier curves of outcome events in patients with posterior stroke stratified by lesion size 
 
 
 
 
